99 studies found for:    Open Studies | "Pulmonary Fibrosis"
Show Display Options
Rank Status Study
21 Unknown  Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
Conditions: Pulmonary Arterial Hypertension;   Idiopathic Pulmonary Fibrosis;   Interstitial Lung Disease;   Pulmonary Hypertension
Intervention: Drug: sildenafil
22 Recruiting Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Other: No Intervention
23 Unknown  Pulmonary Fibrosis and Telomerase Mutation Study
Condition: Pulmonary Fibrosis
Intervention:
24 Not yet recruiting Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Conditions: Interstitial Lung Disease;   Idiopathic Pulmonary Fibrosis
Intervention:
25 Recruiting Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab
Condition: Pulmonary Fibrosis
Interventions: Drug: Bevacizumab;   Drug: Dexamethasone
26 Recruiting Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Matching Placebo;   Drug: Nintedanib
27 Recruiting Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)
Condition: Pulmonary Fibrosis
Intervention:
28 Recruiting Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)
Condition: Pulmonary Fibrosis
Intervention:
29 Unknown  Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis
Condition: Pulmonary Fibrosis
Intervention: Drug: pomalidomide (CC-4047
30 Not yet recruiting Modelling of Quality Life, Clinical and Physiological Measures in Idiopathic Pulmonary Fibrosis
Conditions: Idiopathic Pulmonary Fibrosis;   Dyspnoea;   Anxiety;   Depression
Intervention:
31 Recruiting Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: BMS-986020;   Drug: Placebo matching with BMS-986020
32 Available Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: nintedanib
33 Recruiting Idiopathic Pulmonary Fibrosis Registry for Future Studies
Conditions: Lung Disease, Interstitial;   Idiopathic Pulmonary Fibrosis
Intervention:
34 Not yet recruiting Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idiopathic Pulmonary Fibrosis
Conditions: Idiopathic Pulmonary Fibrosis;   Healthy
Intervention:
35 Recruiting A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: lebrikizumab;   Drug: placebo
36 Recruiting A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Biological: Tralokinumab;   Other: Placebo
37 Recruiting Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
Condition: Idiopathic Pulmonary Fibrosis
Intervention:
38 Not yet recruiting Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: fostair;   Drug: placebo
39 Unknown  Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry
Condition: Idiopathic Pulmonary Fibrosis
Intervention:
40 Recruiting Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Biological: Autologous Stromal Vascular Fraction (SVF);   Biological: Autologous Adipose Derived MSCs (ADMSCs);   Other: Control

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years